Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ARCA biopharma logo — Personalized therapies for cardiovascular disease through ad...

ARCA biopharma

Personalized therapies for cardiovascular disease through advanced genetic research

Founded 1992 Post Ipo Equity Total: $90.45M Biotechnology, Health and Wellness

General Information

Company Name ARCA biopharma
Founded Year 1992
Founders / Decision Makers
Team member
Industries Biotechnology, Health and Wellness
Funding Stage Post Ipo Equity
Social

Get notified when ARCA biopharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ARCA biopharma

ARCA biopharma is a Colorado-based biopharmaceutical company that was founded in 1992. The company's slogan, "Personalized therapies for cardiovascular disease through advanced genetic research," reflects its core focus on developing genetically-targeted therapies for cardiovascular diseases. By integrating expertise in cardiovascular pathophysiology, molecular genetics, and clinical development, ARCA aims to create personalized treatments for cardiovascular disease using genetic information. The company received a significant $51.65MPost-IPO Equity investment on 25 June 2015, with participation from notable investors such as New Enterprise Associates, RA Capital Management, Venrock, Franklin Templeton, and Tekla Capital Management. This investment underscores the market's confidence in ARCA's innovative approach to addressing cardiovascular diseases through advanced genetic research. As the biotechnology industry continues to advance, ARCA biopharma's focus on personalized therapies positions the company at the forefront of genetically-targeted treatments for cardiovascular diseases. With substantial backing from experienced investors, ARCA is well-positioned to advance its mission of leveraging genetic information to develop innovative solutions for cardiovascular health.

Taxonomy: biopharmaceutical company, cardiovascular disease, genetically-targeted therapies, personalized treatments, genetic research, molecular genetics, clinical development, Colorado-based, ARCA biopharma, pathophysiology, personalized therapies

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 5
Investor Investor Investor Investor
•••• •••• 		25 Jun 2015
Post-IPO Equity •••••• - 17 Jun 2013
Post-IPO Equity •••••• - 05 Jan 2012
Series B •••••• 5
Investor Investor Investor Investor
•••• •••• 		12 Jun 2007
Series A •••••• - 03 Mar 2006

ARCA biopharma Alternatives & Competitors

ARCA biopharma vs
Myogen
Myogen

Advancing cardiovascular health with innovative small molecule therapeutics for unmet medical needs.

Series D
Biopharma, Biotechnology
ARCA biopharma vs
Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc. United States

Making cardiovascular disease prevention and early detection more accessible, personalized, and prec...

Post Ipo Debt
17 employees
Biotechnology, Health Care
ARCA biopharma vs
Renovacor
Renovacor

Advancing transformative therapies for cardiovascular disease

Post Ipo Equity
6 employees
Biotechnology, Health Care

FAQ About ARCA biopharma

Personalized therapies for cardiovascular disease through advanced genetic research
ARCA biopharma was founded in 1992.
ARCA biopharma operates in the following industries: Biotechnology, Health and Wellness.
ARCA biopharma has completed 5 funding rounds, raising a total of $90.45M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to ARCA biopharma include Myogen, Cardio Diagnostics Holdings Inc., Renovacor, Vastera, Cardax, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ARCA biopharma and Myogen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ARCA biopharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy